BRCA1/2 testing should be offered to high-risk groups, especially patients with strong familiarity for BRCA-related tumors, an early diagnosis (before the age of 50), a diagnosis of TNBC before the age of 60, male patients with BC, and/or patients with a personal history of ovarian cancer or second BC [3]. The gene discussed is BRCA1; the disease is breast cancer.